BIOLINERX     Print Page  Close Window

SEC filings
6-K
BIOLINERX LTD. filed this Form 6-K on 03/10/2016
Entire Document
 
6

 
 
BioLineRx Ltd.
 
CONSOLIDATED CASH FLOW STATEMENTS

   
Year ended December 31,
 
   
2013
   
2014
   
2015
 
   
in USD thousands
 
CASH FLOWS - OPERATING ACTIVITIES
                 
Net loss
    (17,024 )     (11,076 )     (14,400 )
Adjustments required to reflect net cash used in operating activities (see appendix below)
    (2,501 )     (4,674 )     232  
Net cash used in operating activities
    (19,525 )     (15,750 )     (14,168 )
                         
CASH FLOWS - INVESTING ACTIVITIES
                       
Investments in short-term deposits
    (35,665 )     (57,186 )     (63,130 )
Maturities of short-term deposits
    29,669       37,650       50,083  
Maturities of restricted deposits
    795       -       166  
Purchase of property and equipment
    (85 )     (187 )     (2,683 )
Purchase of intangible assets
    (32 )     (6 )     (36 )
Net cash used in investing activities
    (5,318 )     (19,729 )     (15,600 )
                         
CASH FLOWS - FINANCING ACTIVITIES
                       
Issuance of share capital and warrants, net of issuance costs
    15,108       32,635       29,053  
Proceeds of bank loan
    -       -       467  
Repayments of bank loan
    (37 )     -       (31 )
Proceeds from exercise of employee stock options
    3       -       -  
Net cash provided by financing activities
    15,074       32,635       29,489  
                         
DECREASE IN CASH AND CASH EQUIVALENTS
    (9,769 )     (2,844 )     (279 )
CASH AND CASH EQUIVALENTS - BEGINNING OF YEAR
    18,307       8,899       5,790  
EXCHANGE DIFFERENCES ON CASH AND CASH EQUIVALENTS
    361       (265 )     33  
CASH AND CASH EQUIVALENTS - END OF YEAR
    8,899       5,790       5,544